HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.